US EditionPublished • loading... • Updated
Sorrento Therapeutics (SRNEQ) versus The Competition Head to Head Analysis
Sorrento Therapeutics reported $62.84 million in revenue but faced significant losses and volatility, with 0% institutional ownership, leading to Chapter 11 liquidation approval in 2023.
Summary
1 Articles
1 Articles
Sorrento Therapeutics (SRNEQ) & Its Competitors Critical Comparison
Risk & Volatility Sorrento Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics’ competitors have a beta of -17.14, meaning that their average stock price is 1,814% less volatile than the S&P 500. Earnings & Valuation This table compares Sorrento Therapeutics and its competitors revenue, earnings per share and valuation. Gross Revenue Net Income Price/Earnings…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
